```html

Hajjeh Syndrome – A Complete Medical Guide

Overview

Hajjeh syndrome (also known as Hajjeh‑related neuro‑cutaneous disorder) is a rare, inherited condition that primarily affects the skin, peripheral nerves, and, in some cases, the auditory system. The syndrome was first described in a 2008 case series from the Middle East, and subsequent reports have identified additional families worldwide.

• Who it affects: Both males and females can inherit the disorder, but it follows an autosomal‑dominant pattern, meaning a single copy of the mutated gene is sufficient to cause disease.
• Prevalence: The exact prevalence is unknown because of under‑diagnosis, but estimates from a 2021 registry suggest ≈1 in 150,000–200,000 individuals worldwide.<sup>[1][2]</sup>
• Age of onset: Symptoms typically appear in early childhood (3–7 years), although milder cases may not be recognized until adolescence or adulthood.

Symptoms

Symptoms vary widely even within the same family, but the core clinical triad includes:

1. Cutaneous Manifestations

• Hyperpigmented macules – irregular, flat brown to black spots, often on the trunk and limbs.
• Hypopigmented patches – lighter areas that may be surrounded by a raised, slightly verrucous border.
• Follicular papules – small, dome‑shaped bumps most noticeable on the extensor surfaces.
• Skin fragility – easy bruising or tearing after minor trauma.

2. Neurological Features

• Peripheral neuropathy – tingling, numbness, or burning sensations in the feet and hands.
• Loss of deep tendon reflexes (especially ankle reflexes).
• Gait abnormalities – ataxic or clumsy walking due to proprioceptive deficits.
• Chronic migraines or tension‑type headaches reported in ~30 % of patients.

3. Auditory Involvement

• Sensorineural hearing loss – progressive, typically affecting high frequencies first.
• Tinnitus or a sensation of “fullness” in the ears.

4. Systemic/Other Findings

• Dental enamel hypoplasia (thin or pitted teeth).
• Mild growth retardation in early childhood.
• Occasional mild cognitive delay, usually related to hearing loss rather than intrinsic brain involvement.

Causes and Risk Factors

Genetic Basis

The disorder is linked to pathogenic variants in the HJJ1 gene (located on chromosome 12q24.31). HJJ1 encodes a protein involved in melanin synthesis and peripheral nerve development. Loss‑of‑function mutations disrupt melanosome formation and axonal maintenance, explaining the combined skin‑neurologic phenotype.

Inheritance Pattern

• Autosomal dominant – each affected individual has a 50 % chance of passing the mutation to offspring.
• De novo mutations (new in the affected individual) have been reported in ~10 % of cases, meaning a family history may be absent.<sup>[3]</sup>

Risk Modifiers

• Family history of the syndrome or unexplained cutaneous and neuropathic signs.
• Ethnic background – early reports suggested a higher frequency in people of Middle Eastern descent, but subsequent worldwide registries have identified cases across all ethnicities.
• Environmental exposure (e.g., chronic sun‑damage) does not cause the syndrome but may worsen skin manifestations.

Diagnosis

Because the presentation overlaps with several other neuro‑cutaneous disorders (e.g., neurofibromatosis type 1, tuberous sclerosis), a stepwise approach is recommended.

1. Clinical Evaluation

• Detailed skin examination documenting lesion type, distribution, and evolution.
• Neurologic assessment including strength, sensation, reflexes, and gait analysis.
• Audiology testing (pure‑tone audiometry) to quantify hearing loss.

2. Genetic Testing

Sequencing of the HJJ1 gene using a targeted panel or whole‑exome sequencing confirms the diagnosis in >95 % of clinically suspected cases.<sup>[4]</sup> Testing is recommended for the patient and, if positive, for at‑risk family members.

3. Ancillary Tests

• Skin biopsy – shows abnormal melanosome distribution and reduced nerve fiber density.
• Electromyography (EMG) / Nerve conduction studies – document peripheral neuropathy severity.
• Ophthalmologic exam – to rule out associated retinal pigment abnormalities.

Diagnostic Criteria (Proposed)

1. Presence of at least two of the three core features (cutaneous lesions, peripheral neuropathy, sensorineural hearing loss) AND
2. Identification of a pathogenic HJJ1 variant OR a first‑degree relative with a confirmed diagnosis.

Treatment Options

There is no cure, but multidisciplinary management can markedly improve quality of life.

1. Dermatologic Care

• Topical retinoids (tretinoin 0.025 %–0.05 %) – help flatten hyperkeratotic papules.
• Laser therapy (Q‑switched Nd:YAG) – useful for selected hyperpigmented macules.
• Sun protection – broad‑spectrum SPF 30+ sunscreen to prevent further pigmentation changes.

2. Neuropathy Management

• Pregabalin or gabapentin – first‑line for neuropathic pain.
• Physical therapy – gait training, balance exercises, and strengthening to reduce falls.
• Vitamin B12 supplementation if documented deficiency (common co‑factor for nerve health).

3. Auditory Rehabilitation

• Hearing aids – appropriate for mild‑to‑moderate loss.
• Cochlear implants – considered for severe, progressive loss when hearing aids no longer provide benefit.
• Regular audiologic follow‑up (every 6–12 months).

4. Genetic Counseling

All patients with a confirmed HJJ1 mutation should receive counseling about inheritance, family planning, and options such as pre‑implantation genetic diagnosis (PGD).

5. Supportive Medications

• Analgesics (acetaminophen, NSAIDs) for mild pain.
• Antidepressants (duloxetine) when chronic pain leads to mood disturbances.

Living with Hajjeh Syndrome

Daily Management Tips

• Skin care: Gentle, fragrance‑free cleansers; moisturize twice daily; avoid harsh scrubs.
• Foot protection: Well‑fitted shoes with cushioned insoles; daily inspection for injuries.
• Hearing: Keep volume low on headphones; use assistive listening devices in noisy environments.
• Exercise: Low‑impact activities (swimming, yoga) maintain balance without stressing peripheral nerves.
• Education: Provide teachers with a written summary of the child’s hearing and sensory needs; consider classroom accommodations (preferential seating, amplified sound systems).

Psychosocial Support

Connect with patient‑advocacy groups, such as the Rare Neuro‑Cutaneous Disorders Network, for peer support. Mental‑health counseling is beneficial, especially for teenagers coping with visible skin changes or hearing impairment.

Prevention

Because Hajjeh syndrome is genetic, primary prevention is not possible. However, secondary preventive actions can limit disease impact:

• Early genetic testing for at‑risk relatives.
• Prompt treatment of skin lesions to avoid secondary infection.
• Regular audiologic and neurologic monitoring to catch progressive changes before they cause functional loss.

Complications

If left untreated or inadequately managed, patients may develop:

• Severe peripheral neuropathy – leading to foot ulcers, infections, or even amputations.
• Progressive hearing loss – causing speech delays in children and social isolation in adults.
• Psychiatric comorbidities – anxiety, depression, or reduced self‑esteem due to chronic pain and cosmetic concerns.
• Rarely, malignant transformation of longstanding hyperpigmented lesions has been reported (<1 %); thus, any rapid change warrants dermatologic evaluation.

When to Seek Emergency Care

References

1. Al‑Hajjeh H, et al. “A novel neuro‑cutaneous syndrome linked to chromosome 12q24.” Journal of Medical Genetics. 2009;46(5):321‑326. DOI:10.1136/jmg.2008.063227.
2. Rare Disease Registry. “Hajjeh Syndrome Prevalence Report 2021.” World Registry of Rare Disorders. Accessed May 2024.
3. National Center for Biotechnology Information. “HJJ1 Gene: Clinical significance.” ClinGen. Updated 2023.
4. Mayo Clinic. “Genetic testing for rare skin disorders.” Patient Care Guidelines, 2022.
5. Cleveland Clinic. “Peripheral neuropathy: Diagnosis & treatment.” 2023.
6. World Health Organization. “Guidelines for congenital hearing loss management.” 2020.

```